Lantheus Joins FIBRE Consortium with Pfizer, Lumina to Revolutionize Fibrotic Disease Treatment
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus Holdings announced its participation in the newly launched FIBRE Consortium, which is a collaborative initiative with Pfizer Inc. (NYSE:PFE) and Lumina Pharmaceuticals. The consortium's primary goal is to revolutionize the treatment of fibrotic diseases by using advanced imaging biomarkers.
The FIBRE (Fibrosis Imaging Biomarker Research & Evaluation) Consortium aims to accelerate biomarker validation and reduce the costs of clinical trials for fibrotic diseases through innovative imaging technologies. Lantheus's contribution includes supplying LNTH-1363S, which is a PET tracer targeting Fibroblast Activation Protein/FAP. FAP is a protein expressed exclusively by activated fibroblasts.
A medical professional performing a pulmonary function assessment on a patient.
This biomarker, along with Lumina's [⁶⁸Ga]CBP8 PET/MRI tracer for Collagen Type I, will enable the quantification of fibrosis burden and treatment response within weeks, and potentially reduce trial durations by 60% and costs by ~$400 million. Initial studies will focus on Metabolic Dysfunction-Associated Steatohepatitis/MASH, with potential expansion into other fibrotic conditions.
Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist in the diagnosis and treatment of heart, cancer, and other diseases.
While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the .
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Jeff Bezos and Lauren Sánchez are one of the richest married couples. Here's how the ultrawealthy do prenups.
With Jeff Bezos and Lauren Sánchez now married, they're likely to have a complex prenup. Lawyers and wealth management experts outlined the prenup process for the superrich. Business control, property ownership, and trusts are just some of the questions prenups tackle. Hindsight is 20/20 — especially when hindsight is worth $38 billion. Amazon founder Jeff Bezos and MacKenzie Scott, his first wife, got married without a prenup (in 1993, before Bezos started Amazon). Scott received roughly $38 billion in Amazon shares in the settlement, making her one of the world's richest women. On Friday, Bezos got married again, this time to helicopter pilot and former journalist Lauren Sánchez. Experts in family law and wealth management told Business Insider that the couple is almost certain to have a complex prenup. Bezos is, after all, worth more than $200 billion today. A representative for Bezos didn't respond to a request for comment from BI about whether the couple has a prenup. Anne Paape, the managing director and head of wealth strategy at Cresset Capital, a multi-family office for entrepreneurs and multi-generational families of wealth, said prenups are generally becoming more common and are sometimes even mandated in family trusts for the ultrawealthy. Prenups begin with both people fully disclosing their financial assets and debts, she said. Besides family, they can also involve everyone from business partners and tax attorneys to luxury realtors and aviation experts who help appraise homes and private jets, said Brooke Summerhill, a divorce financial consultant who primarily works with ultra-high net worth clients. "It's not the clients making a lot of these decisions, it's their team helping them understand what those decisions are and making those decisions with them," she told BI. Paape doesn't know the details of Bezos' potential prenup but said his situation isn't entirely unique: Many superrich weddings mark second or third marriages for at least one spouse, often one whose assets have changed considerably since their first time tying the knot. "He will absolutely have protection against anything that he could," Summerhill said, adding that he likely won't let his pre-marriage assets co-mingle with Sánchez's assets. The more money you have, the more potential prenup headaches you'll have, especially when it comes to business interests and properties. Wealthy clients tend to have properties and business interests around the globe, making it harder to ensure compliance with divorce and death laws in various jurisdictions. Many entrepreneurs like Bezos are focused on insulating their businesses in the event of a divorce or death. Most don't want to risk giving an ex-partner enough stock to have a say in how the company runs, Paape told BI. "You could try to compensate for keeping that off the table," Paape said. "What else if you were to get divorced? What other resources could you provide to that person?" Clauses safeguarding the appreciation of assets during a marriage are also key for wealthy clients, Summerhill said. If the couple ever divorces, it's not unlikely that Sánchez would get a lump sum, Amazon shares, and some real estate, according to Summerhill and Raymond Hekmat, a family law attorney in Beverly Hills who primarily writes prenups. But a marriage can also end in death, and that's where a death clause can come in. As Summerhill put it, this "prevents the surviving spouse from claiming a bigger portion of that deceased person's separate property." A surviving spouse commonly receives a lump sum or life insurance payout upon their spouse's death, she said, but a last will and testament may take precedent over the prenup. Prenups for the ultrawealthy have repercussions beyond the couple, whether it's about who takes over the family empire or gets the keys to the Hamptons home. "There's more people that care about the resolution of that breakup, whether it's divorce or death," Paape said. "It's business partners, it's employees, it's charities you support, it's children and grandchildren." She said trusts "are a no-brainer " for children of the ultrarich and that many provisions deal with inherited property or business ownership. Bezos shares four children with Scott, and Sánchez has three kids. Hekmat said all the prenups he draws up have a confidentiality provision, and some can include social media restrictions. "In the event of a breakup, you can't disparage the other party or discuss the prenup in any way with the public, and there could be penalties involved," he said. Prenups can also include sunset clauses, which say that some provisions or even the full agreement expires after a certain period of time. Some people may choose to change certain provisions and become more generous after they've been with their spouse for a while, Paape said. Hekmat said that even with prenups, couples risk messy legal and financial fights down the line. Proclaimed love and devotion aside, he kept his advice for the Bezoses of the world simple. "My bottom line for billionaires is don't get married." Have a tip or a story to share about your own experiences with a prenup? Contact these reporters via email at atecotzky@ or sjackson@ or on Signal at alicetecotzky.05. Use a personal email address and a nonwork device; here's our guide to sharing information securely. Read the original article on Business Insider
Yahoo
7 minutes ago
- Yahoo
Meta hires four more OpenAI researchers, The Information reports
(Reuters) -Meta Platforms is hiring four more OpenAI artificial intelligence researchers, The Information reported on Saturday. The researchers, Shengjia Zhao, Jiahui Yu, Shuchao Bi and Hongyu Ren have each agreed to join, the report said, citing a person familiar with their hiring. Earlier this week, the Instagram parent hired Lucas Beyer, Alexander Kolesnikov and Xiaohua Zhai, who were all working in OpenAI's Zurich office, the Wall Street Journal reported. Meta and ChatGPT maker OpenAI did not immediately respond to a Reuters request for comment. The company has recently been pushing to hire more researchers from OpenAI to join chief executive Mark Zuckerberg's superintelligence efforts. Reuters could not immediately verify the report.
Yahoo
7 minutes ago
- Yahoo
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8. STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. "With our expertise in primary hemophagocytic lymphohistiocytosis, we understand the urgency of managing MAS quickly to improve patient outcomes," said Guido Oelkers, Chief Executive Officer at Sobi. "Gamifant is already an established therapy making a meaningful difference for patients with primary HLH, and with this approval, we are excited about the opportunity to positively impact patients affected by MAS in Still's Disease". The approval is based on results of the pooled data from two pivotal studies, the Phase 3 study (NCT05001737) and NI-0501-06 (NCT03311854). 54 percent (21/39) of patients had a complete response at Week 8, and 82% (32/39) achieved clinical MAS remission (VAS ≤1 cm) at Week 8. Safety and tolerability were consistent with previous clinical studies. In patients with HLH/MAS in Still's disease, the most common adverse events (≥20%) were viral infections, including cytomegalovirus infection or reactivation, and rash. "MAS in Still's disease is a serious and potentially life-threatening complication, marked by severe hyperinflammation and, in some cases, multi-organ failure," said Alexei A. Grom, MD, Professor of Pediatrics, Research Director Division of Rheumatology, Cincinnati Children's Hospital Medical Center. "Many patients affected by MAS—both young children and adults—face significant unmet medical needs. With Gamifant now as the first FDA-approved treatment for MAS, we have a new therapeutic option that helps control hyperinflammation and reduce our reliance on high-dose glucocorticoids." MAS, a form of HLH, is a severe complication of rheumatic diseases, occurring most frequently in Still's disease including systemic juvenile idiopathic arthritis and adult-onset Still's disease. HLH/MAS is a rare systemic disorder of interferon gamma (IFNy) driven hyperinflammation with common clinical manifestations such as high persistent fever, elevated ferritin, cytopenias, coagulopathies, and hepatosplenomegaly. Gamifant, an interferon gamma (IFNγ)–blocking antibody, is the first and only FDA approved treatment for adult and pediatric (newborn and older) patients with primary HLH with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. U.S. Indication for Gamifant® (emapalumab-lzsg) Please see the full Prescribing Information for Gamifant. About macrophage activation syndrome (MAS) Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases, most frequently in Still's disease including systemic juvenile idiopathic arthritis (sJIA) – a rare systemic disorder of auto-inflammatory nature with common clinical manifestations such as daily spiking fever, typical transient cutaneous rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities and hyperferritinaemia, possibly progressing to multiple organ failure and death. MAS is classified as a secondary form of haemophagocytic lymphohistiocytosis (HLH). About Gamifant® (emapalumab-lzsg) Gamifant® (emapalumab-lzsg) is the only approved anti-interferon gamma (IFNγ) monoclonal antibody. Gamifant works by binding to and neutralizing IFNγ. When IFNγ is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour. Gamifant is approved in the US for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still's disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 28 June 2025 at 00:55 CEST. Gerard TobinHead of Investor Relations This information was brought to you by Cision The following files are available for download: FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease View original content: Sign in to access your portfolio
